Cargando…

CALR mutation analysis is not indicated in patients with splanchnic vein thrombosis without evidence of a myeloproliferative neoplasm: a micro-review

Detalles Bibliográficos
Autor principal:	Langabeer, Stephen E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hellenic Society of Gastroenterology 2016
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049572/ https://www.ncbi.nlm.nih.gov/pubmed/27708531 http://dx.doi.org/10.20524/aog.2016.0057

Ejemplares similares

Detecting CALR Mutations in Splanchnic Vein Thrombosis: Who and How?
por: Langabeer, Stephen E.
Publicado: (2018)

CALR mutations in myeloproliferative neoplasms: An unfolding story
por: Langabeer, Stephen E.
Publicado: (2020)

Concurrent chronic myeloid leukemia and CALR-mutated myeloproliferative neoplasm
por: Langabeer, Stephen E.
Publicado: (2020)

Splanchnic vein thrombosis in myeloproliferative neoplasms: treatment algorithm 2018
por: Finazzi, Guido, et al.
Publicado: (2018)

Splanchnic Vein Thrombosis in Myeloproliferative Neoplasms: Treatment Considerations and Unmet Needs
por: Liu, Angela, et al.
Publicado: (2022)

CALR mutation characterization in myeloproliferative neoplasms
por: Bilbao-Sieyro, Cristina, et al.
Publicado: (2016)

P1026: COMPARATIVE GENOMIC PROFILING OF MYELOPROLIFERATIVE NEOPLASMS PRESENTING WITH AND WITHOUT SPLANCHNIC VEIN THROMBOSIS
por: Garrote, M., et al.
Publicado: (2022)

Splanchnic vein thrombosis, the onset manifestation in JAK positive Chronic Myeloproliferative Disorders Neoplasms
por: Vladareanu, AM, et al.
Publicado: (2011)

Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients
por: De Stefano, V, et al.
Publicado: (2016)

The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms
por: Belčič Mikič, Tanja, et al.
Publicado: (2021)

Hypercalcemia as a biomarker of myeloproliferative neoplasms?
por: Langabeer, Stephen E.
Publicado: (2019)

Dual Drivers in the Myeloproliferative Neoplasms: An Underestimation?
por: Langabeer, Stephen E.
Publicado: (2023)

Myeloproliferative neoplasm-driving Calr frameshift promotes the development of pulmonary hypertension in mice
por: Minakawa, Keiji, et al.
Publicado: (2021)

Circulating Endothelial Cell Levels Correlate with Treatment Outcomes of Splanchnic Vein Thrombosis in Patients with Chronic Myeloproliferative Neoplasms
por: Giordano, Giulio, et al.
Publicado: (2022)

γ-Glutamyl Transferase Is an Independent Biomarker of Splanchnic Thrombosis in Patients With Myeloproliferative Neoplasm
por: Görtzen, Jan, et al.
Publicado: (2016)

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms
por: Pietra, D, et al.
Publicado: (2016)

MPL exon 10 mutations in Irish patients with a suspected myeloproliferative neoplasm
por: Lee Tokar, Lisa, et al.
Publicado: (2021)

Sequential evaluation of CALR mutant burden in patients with myeloproliferative neoplasms
por: Cavalloni, Chiara, et al.
Publicado: (2017)

Development of paroxysmal nocturnal hemoglobinuria in CALR-positive myeloproliferative neoplasm
por: Fraiman, Yarden S, et al.
Publicado: (2016)

Effects of CALR-Mutant Type and Burden on the Phenotype of Myeloproliferative Neoplasms
por: Kim, Hyun-Young, et al.
Publicado: (2022)

Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms
por: Guo, Haixiu, et al.
Publicado: (2015)

Molecular screening for an underlying myeloproliferative neoplasm in patients with stroke: who and how?
por: Langabeer, Stephen E.
Publicado: (2020)

Acute promyelocyte leukemia arose from CALR 1 mutated post essential thrombocythemia- myelofibrosis with splanchnic vein thrombosis: A case report
por: Morsia, E, et al.
Publicado: (2021)

High Frequency of Endothelial Colony Forming Cells Marks a Non-Active Myeloproliferative Neoplasm with High Risk of Splanchnic Vein Thrombosis
por: Rosti, Vittorio, et al.
Publicado: (2010)

Management of splanchnic vein thrombosis
por: Elkrief, Laure, et al.
Publicado: (2023)

Correction: Frequencies, Laboratory Features, and Granulocyte Activation in Chinese Patients with CALR-Mutated Myeloproliferative Neoplasms
por: Guo, Haixiu, et al.
Publicado: (2015)

CALR Mutation Underlying Silent Stroke
por: Faryal, Rehman, et al.
Publicado: (2021)

The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
por: Wu, Zhiyuan, et al.
Publicado: (2014)

Splanchnic Vein Thrombosis: Current Perspectives
por: Valeriani, Emanuele, et al.
Publicado: (2019)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

Molecular screening for an underlying myeloproliferative neoplasm in rheumatology patients
por: Langabeer, Stephen
Publicado: (2022)

Clonal hematopoiesis by DNMT3A mutations as a common finding in idiopathic splanchnic vein thrombosis
por: Carrà, Giovanna, et al.
Publicado: (2022)

CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
por: Belcic Mikic, Tanja, et al.
Publicado: (2019)

Megakaryocytes, erythropoietic and granulopoietic cells express CAL2 antibody in myeloproliferative neoplasms carrying CALR gene mutations
por: Ali, Hebah, et al.
Publicado: (2020)

Low-level somatic JAK2 V617F mutation in myelodysplastic/ myeloproliferative neoplasm with ring sideroblasts, and thrombocytosis with co-mutated SF3B1 and CALR
por: Ji, Young Sok, et al.
Publicado: (2022)

Splanchnic Vein Thrombosis in the Mediterranean Area in Children
por: El-Karaksy, Hanaa, et al.
Publicado: (2011)

Splanchnic Vein Thrombosis: Etiology, Diagnosis, and Treatment
por: Qi, Xingshun, et al.
Publicado: (2015)

Shedding Light on the Pathogenesis of Splanchnic Vein Thrombosis
por: Camerlo, Sofia, et al.
Publicado: (2023)

Idiopathic splanchnic vein thrombosis: is it really idiopathic?
por: Barosi, Giovanni
Publicado: (2022)

Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms
por: Singdong, Roongrudee, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_6nc2p3s0en3b6ph3486lnesrle